Klara Gaćina

Dr. Klara Gaćina

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Acta Clinica Croatica
Verified
Journal Article
Open access
PDF file
KGKlara Gaćina
Klara Gaćina
AĆAnđela Krstanović Ćosić
Anđela Krstanović Ćosić
Tranexamic acid is a synthetic derivative of the amino acid lysine, an antifibrinolytic that is primarily used to reduce bleeding in surgery, trauma, and dental procedures. Its anti-inflammatory and anti-angiogenic properties, as well as its abilit...

4 August 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
IPIvana Prkacin
Ivana Prkacin
Ana BrkićAna Brkić
Ana Brkić
NPNives Pondeljak
Nives Pondeljak
MMMislav Mokos
Mislav Mokos
KGKlara Gaćina
Klara Gaćina
MSMirna Situm
Mirna Situm
Background: Patients with resected stage IIB and IIC melanoma are at high risk of recurrence and distant metastasis, despite surgical treatment. The recent emergence of immune checkpoint inhibitors (ICIs) has led to their evaluation in the adjuvant setting for early-stage disease. This review aims to synthesize current evidence regarding adjuvant immunotherapy for stage IIB/IIC melanoma, explore emerging strategies, and highlight key challenges and future directions. Methods: We conducted a comprehensive literature review of randomized clinical trials, observational studies, and relevant mechanistic and biomarker research on adjuvant therapy in stage IIB/IIC melanoma. Particular focus was placed on pivotal trials evaluating PD-1 inhibitors (KEYNOTE-716 and CheckMate 76K), novel vaccine and targeted therapy trials, mechanisms of resistance, immune-related toxicity, and biomarker development. Results: KEYNOTE-716 and CheckMate 76K demonstrated significant improvements in recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) with pembrolizumab and nivolumab, respectively, compared to placebo. However, no definitive overall survival benefit has yet been shown. Adjuvant immunotherapy is linked to immune-related adverse events, including permanent endocrinopathies. Emerging personalized approaches, such as circulating tumor DNA monitoring and gene expression profiling, may enhance patient selection, but remain investigational. Conclusions: Adjuvant PD-1 blockade offers clear RFS benefits in high-risk stage II melanoma, but optimal patient selection remains challenging, due to uncertain overall survival benefit and toxicity concerns. Future trials should integrate biomarker-driven approaches to refine therapeutic decisions and minimize overtreatment.

15 August 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
MMMislav Mokos
Mislav Mokos
IPIvana Prkacin
Ivana Prkacin
KGKlara Gaćina
Klara Gaćina
Ana BrkićAna Brkić
Ana Brkić
NPNives Pondeljak
Nives Pondeljak
MSMirna Situm
Mirna Situm
Background: Melanoma is one of the most aggressive types of skin cancer. Its diagnosis appears to be challenging due to morphological similarities to benign melanocytic lesions. Even though histopathological evaluation is the diagnostic gold standard, immunohistochemistry (IHC) proves to be useful in challenging cases. Preferentially Expressed Antigen in Melanoma (PRAME) has emerged as a promising diagnostic, prognostic, and therapeutic marker in melanoma. Methods: This review critically examines the role of PRAME across clinical domains. It presents an evaluation of PRAME’s diagnostic utility in differentiating melanomas from benign nevi, its prognostic significance across melanoma subtypes, and therapeutic applications in emerging immunotherapy strategies. An extensive analysis of the current literature was conducted, with a focus on PRAME expression patterns in melanocytic lesions and various malignancies, along with its integration into IHC protocols and investigational therapies. Results: PRAME demonstrates high specificity and sensitivity in distinguishing melanoma from benign melanocytic proliferations, particularly in challenging subtypes such as acral, mucosal, and spitzoid lesions. Its overexpression correlates with poor prognosis in numerous malignancies. Therapeutically, PRAME’s HLA class I presentation enables T-cell-based targeting. Early-phase trials show promising results using PRAME-directed TCR therapies and bispecific ImmTAC agents. However, immune evasion mechanisms (i.e., heterogeneous antigen expression, immune suppression in the tumor microenvironment, and HLA downregulation) pose significant challenges to therapy. Conclusions: PRAME is a valuable biomarker for melanoma diagnosis and a promising target for immunotherapy. Its selective expression in malignancies supports its clinical utility in diagnostic precision, prognostic assessment, and precision oncology. Ongoing research aimed at overcoming immunological barriers will be essential for optimizing PRAME-directed therapies and establishing their place in the personalized management of melanoma.

1 January 2022 in Acta Clinica Croatica
Verified
Journal Article
Open access
PDF file
KGKlara Gaćina
Klara Gaćina
MLMladen Lešin
Mladen Lešin
DSDean Sarajčev
Dean Sarajčev
NRNina Rotim
Nina Rotim
The aim of this study was to determine the effect of botulinum toxin type A and satisfaction in patients with essential blepharospasm. The study included 12 subjects suffering from essential blepharospasm who received therapy with botulinum toxin t...

15 February 2026 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
PNPaola Negovetic
Paola Negovetic
KGKlara Gaćina
Klara Gaćina
NFNika Franceschi
Nika Franceschi
MBMarija Buljan
Marija Buljan
Background: Cutaneous melanoma is an aggressive malignancy driven by complex interactions between tumor cells and the host immune system. Tumor progression is shaped not only by intrinsic tumor characteristics but also by immune-mediated processes within the tumor microenvironment. Cytokines, particularly interleukins, are key regulators of inflammation, immune cell recruitment, and tumor behavior. Cytokine profiling provides an integrated assessment of soluble immune mediators from tumor and stromal cells, reflecting both local and systemic immune responses. Methods: This narrative review summarizes and synthesizes the current literature addressing the biological and clinical relevance of selected interleukins, including IL-6, IL-8, IL-10, IL-2, IL-17, and IL-18, in cutaneous melanoma. Published data were evaluated with a focus on their immunomodulatory functions and potential implications for prognostic assessment. Results: Interleukins demonstrated distinct and context-dependent prognostic and predictive relevance in cutaneous melanoma. Elevated IL-2 levels correlated with sentinel lymph node positivity, supporting its prognostic value in early disease. Increased circulating IL-6 and IL-8 were consistently associated with tumor burden, advanced disease, and reduced survival. IL-10 expression reflected tumor progression and immune modulation. IL-17 signatures predicted response to combined immune checkpoint inhibition, particularly in BRAFV600-mutant melanoma. IL-18 exhibited dual roles, associating with both immune activation and favorable outcomes depending on tumor context. Conclusions: Interleukin profiling offers a biologically relevant framework for understanding immune regulation in cutaneous melanoma. Integrating interleukin signatures into prognostic models may support more refined risk stratification and advance the implementation of personalized medicine approaches in melanoma management.

25 September 2025 in Cosmetics
Verified
Journal Article
Open access
PDF file
NFNika Filipović
Nika Filipović
PNPaola Negovetic
Paola Negovetic
KGKlara Gaćina
Klara Gaćina
MBMarija Buljan
Marija Buljan
Dermoscopy is an essential, non-invasive diagnostic tool that has transformed the evaluation of pigmented skin lesions and is nowadays also increasingly recognized for its utility in general dermatology. Originally developed for the early detection of melanoma, dermoscopy now aids in diagnosing a wide range of non-neoplastic skin disorders—including inflammatory, infectious, and infiltrative conditions—by revealing morphological features invisible to the naked eye. Among these, facial dermatoses represent a diagnostically challenging group of disorders with overlapping clinical presentations. This review provides a comprehensive overview of the latest literature on dermoscopy in general dermatology, with a specific focus on facial dermatoses. Relevant information for this article was obtained through a comprehensive PubMed search using disease names along with the terms ‘dermoscopy’ and ‘dermatoscopy’. Despite its growing relevance, this field remains underexplored, largely due to the lack of standardized dermoscopic criteria and inconsistent terminology, which pose challenges to broader clinical implementation. Nonetheless, current evidence highlights the promising role played by dermoscopy as an adjunctive diagnostic method, particularly when used by experienced clinicians in combination with detailed patient history and clinical examination. Dermoscopy of facial dermatoses has the potential to significantly improve diagnostic precision in everyday practice. With continued research, greater standardization, and wider clinician training, dermoscopy is well-positioned to become as integral to the diagnosis of inflammatory and infectious dermatoses as it is to skin cancer detection.